Evidence map›Paper›PMID 39906181›Full record

ArticleJTO clinical and research reports2025

Hiroyuki Fujii, Yusuke Okuma, Makoto Hirata, Yuki Shinno, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hiroyuki FujiiDepartment of Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo, Japan.
Yusuke OkumaDepartment of Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo, Japan.
Makoto HirataDepartment of Genetic Medicine and Services, National Cancer Center Hospital, Chuo, Tokyo, Japan.
Yuki ShinnoDepartment of Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo, Japan.
Tatsuya YoshidaDepartment of Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo, Japan.
Yasushi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo, Japan.
Hidehito HorinouchiDepartment of Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo, Japan.
Noboru YamamotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo, Japan.
Yuichiro OheDepartment of Thoracic Oncology, National Cancer Center Hospital, Chuo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comprehensive genomic profiling (CGP) has progressed rapidly and plays an important role in advancing precision medicine in oncology. However, CGP provides opportunities for molecular-targeted therapy, but it also unveils incidental germline findings, posing challenges and opportunities in patient care. We present the case of a 32-year-old female patient, diagnosed with stage IVB lung adenocarcinoma harboring an

Indexed as

Case reportEGFR mutationLi–Fraumeni syndromeLung adenocarcinoma

Identifiers

PMID39906181
PMCPMC11791262

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.